Emerald Health Pharmaceuticals is collaborating with researchers and key opinion leaders at international centers of excellence to leverage multi-disciplinary expertise in drug delivery, formulation, and development. Our research collaborations provide EHP with the optimal platform on which to pursue the development of new therapies for neurodegenerative, autoimmune, and other diseases.

University Complutense (Madrid, Spain)

The Complutense University of Madrid is a public research university located in Madrid, and one of the oldest universities in the world. EHP-102 has been evaluated in preclinical models of Parkinson´s disease and amyotrophic lateral sclerosis (ALS) in collaboration with Prof. Javier Fernandez-Ruiz, a full Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results of these studies have been published in the Journal of Neuroinflammation (2018), Molecules (2019), Biochemical Pharmacology (2018) and Scientific Reports (2016).

The proneurogenic activity of EHP-102 on neuronal stem cells has been demonstrated in preclinical models of Huntington’s disease (HD) in collaboration with Dr. Ismael Galve-Roperh, an Associate Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results in the HD model have been published in Scientific Reports (2016) and Translational Neurodegeneration (2019)

Cajal Institute, Spanish National Research Council

The Cajal Institute (IC) is a research center in neurobiology, which belongs to the Spanish National Research Council (CSIC). EHP-101 has been evaluated in preclinical models of multiple sclerosis (MS), such as the experimental autoimmune encephalomyelitis (EAE) and the Theiler’s virus-induced encephalopathy (TMEV) murine models, in collaboration with Dr. Carmen Guaza, a full Professor at the Cajal Institute, Spanish National Research Council (Madrid, Spain). The data on the hypoxia mimetic activity of EHP-101 have been reported in the Journal of Neuroinflammation (2018).

University of Florida

The University of Florida is a top-ranked public research university located in Gainesville. The active pharmaceutical ingredient (API) in our lead product candidate (EHP-101) is currently under evaluation in preclinical models of stroke, in collaboration with Dr. Eduardo Candelario-Jalil, an Associate Professor at the University of Florida.

Hospital Clínico de San Carlos

The San Carlos Clinical Hospital is located in the city of Madrid and administered by the Madrid Health Service, under the Ministry of Health of the Community of Madrid. Our lead new chemical entities (NCEs) are currently under evaluation in preclinical models of neonatal stroke, in collaboration with Dr. José A. Martinez-Orgado, Head of the Department of Neonatology, Hospital Clínico “San Carlos”.

Maimónides Institute for Biomedical Research (IMIBIC) – University of Córdoba

The Maimonides Biomedical Research Institute of Cordoba – IMIBIC, is a joint Institute of the University of Cordoba (UCO), the Reina Sofia University Hospital, and the Junta de Andalucía Regional government. IMIBIC brings together scientific research and medical practice to embrace integral projects with the ultimate aim to promote a much faster and efficient communication between clinical and preclinical research, and to generate knowledge of high impact with considerable potential of translation into practice, new therapies and innovative products.

VCE-004.8 has been evaluated in a preclinical model of metabolic syndrome induced by high fat diet in collaboration with Dr. Manuel Tena-Sempere, a full Professor of Physiology at the University of Córdoba (IMIBIC). The data on the anti-obesity activity of VCE-004.8 have been reported in the Scientific Reports (2018). In addition, a collaboration is ongoing with the proteomic unit and Prof. Eduardo Muñoz at the IMBIC to analyze plasmatic drug-related biomarkers.

Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche- Università del Piemonte Orientale

The Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche- Università del Piemonte Orientale is located in the city of Novara, Italy. To expand our library of compounds, we are creating additional new molecules in collaboration with Dr. Giovanni Appendino, a full Professor of Organic Chemistry. Prof. Appendino also participated in the discovery of our lead candidates VCE-004.8 and VCE-003.2.